Combined recognition strategy allows CAR T cells to kill solid tumors in mice and avoid side effects
(American Association for the Advancement of Science) Two teams have created a new generation of highly specific CAR T cells, which safely cleared solid tumors in mice with mesothelioma, ovarian cancer, and the deadly brain cancer glioblastoma while outlasting and outperforming conventional CAR T cell designs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2021 Category: Cancer & Oncology Source Type: news

Scientists Develop Artificial Intelligence for Mesothelioma Assessment
Scientists in Scotland have developed a prototype imaging system using artificial intelligence that has proven effective with malignant mesothelioma, potentially revolutionizing the way patients will be treated in the future. The pilot program could spark much-needed advances in diagnostics and therapeutics. “Mesothelioma is such a complex, incredibly difficult disease,” Dr. Kevin Blythe, professor of respiratory medicine at University of Glasgow and respiratory physician at Queen Elizabeth University Hospital, told The Mesothelioma Center at Asbestos.com. “This could be a very important step toward helping pat...
Source: Asbestos and Mesothelioma News - April 26, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Pleural Mesothelioma Patients with 5-Year Survival Still Rare
Although no amount of asbestos exposure is considered safe, lower levels of non-occupational exposure are most often linked to long-term survival for those diagnosed with malignant pleural mesothelioma, according to a recent study. Clinical Lung Cancer published the study that compared characteristics of 43 pleural mesothelioma patients who survived at least five years with the disease to a much larger control group. Several previous mesothelioma studies have estimated that the five-year survival rate is just under 5% for pleural mesothelioma, an aggressive cancer with no definitive cure. It is caused almost exclusiv...
Source: Asbestos and Mesothelioma News - April 22, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Triple combination therapy shows promise against a rare deadly asbestos cancer
(University Health Network) Combining immune-boosting drugs with radiation and surgery increased the survival and anticancer immune response in mouse models of mesothelioma in preclinical research by Princess Margaret Cancer Centre researchers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news

Latest KCIC Report Finds Decline in Mesothelioma Lawsuits
The number of mesothelioma lawsuits filed in 2020 dropped significantly, while cases involving lung cancer continued to increase, according to a recent study reflecting the changing face of asbestos litigation. KCIC, a well-respected consulting firm in Washington, D.C., that manages asbestos product liabilities, released its industry report Thursday. Asbestos legal filings, covering both malignant and nonmalignant disease in the United States, dropped 11% from 2019 to 2020, from 4,137 to 3,685 cases, respectively. Most prominently, there was a 9% increase in asbestos-related lung cancer filings, but a 14% decrease...
Source: Asbestos and Mesothelioma News - April 12, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R – is to determine h...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

COVID Vaccine Gives Less Protection for Some Cancer Patients
Millions of people across the United States have begun receiving their COVID-19 vaccines, and restrictions are lifting in many public spaces such as restaurants and bars. Mesothelioma patients may be looking forward to returning to life as it was before the pandemic. However, a new study reports that the COVID-19 vaccine may not sufficiently protect patients with compromised or weakened immune systems. The study results suggest that people with cancer or who are undergoing cancer treatment may still be highly vulnerable to COVID-19 even after their vaccination. Researchers published their findings earlier this m...
Source: Asbestos and Mesothelioma News - March 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Thoracic Surgeon Raja Flores Enters NYC Mayor ’s Race
Thoracic surgeon and mesothelioma specialist Dr. Raja Flores wants to continue serving others, but in a new role as the next mayor of New York City. “Yes, I’m serious about this. Very serious,” Flores told The Mesothelioma Center at Asbestos.com Tuesday after another 14-hour workday and an evening surgery at Mount Sinai. “I want to take care of this city that has taken such good care of me.” Flores, the esteemed chairman of thoracic surgery at Mount Sinai Hospital, filed his official eligibility petition last week with the New York City Board of Elections. He listed himself as an independent, joining mor...
Source: Asbestos and Mesothelioma News - March 25, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Some Mesothelioma Patients May Benefit from Second Radical Surgery
This study should elicit a call of hands for centers to share their experiences, to say either do it, or not do it,” Elsayed said. “Right now, you just don’t find a good number of centers doing that second operation.” Earlier Mesothelioma Surgery Studies  This most recent report focused on three smaller studies totaling 40 patients involved in a second major surgery with a curative intent for mesothelioma. In the first group of 16 patients, there was a median survival of 20.4 months after the second surgery for those with epithelial cell type, but only 7.4 months survival for those with biphasic subty...
Source: Asbestos and Mesothelioma News - March 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma
(ECOG-ACRIN Cancer Research Group) The DREAM3R phase 3 clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. DREAM3R aims to enroll 480 patients with non-epithelioid or epithelioid subtype. Patients will be randomized 2:1 to receive durvalumab immunotherapy plus 4-6 cycles of chemotherapy or chemotherapy alone. Patients in the experimental group will continue to receive durvalumab after chemotherapy until disease progression, unacceptable toxicity, or patient withdrawal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

U.S. Asbestos Imports Increased Significantly in 2020
An estimated 300 metric tons of raw chrysotile asbestos was imported into the U.S. in 2020, almost doubling the amount from 2019, according to the recent United States Geological Survey Mineral Commodity Summaries report. The chloralkali industry accounted for 100% of the imports, all from Brazil. This industry uses the asbestos in the manufacturing of semipermeable diaphragms for making chlorine. Asbestos import numbers were the second smallest in more than 50 years and only a fraction of the all-time high of 803,000 tons reported in 1973. Also imported into the United States, but not included in the report, is a...
Source: Asbestos and Mesothelioma News - March 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Link Between Women with Mesothelioma and Survival Genes
Men with mesothelioma outnumber women four to one. However, numerous studies have shown that women with mesothelioma often have a survival advantage over men. Now, scientists might have a better understanding of why. Researchers have identified a gene that predicts the prognosis and treatment outcome for women with malignant pleural mesothelioma. The research took place as part of the International Mesothelioma Program at Brigham and Women’s Hospital in Boston. Dr. Assunta De Rienzo led the new study after years of research highlighting the sex-based disparity among mesothelioma patients. “The goal is finding ...
Source: Asbestos and Mesothelioma News - March 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Legal Fight Continues Over Asbestos Disease in Libby, Mont.
The Center for Asbestos Related Disease in Libby, Montana, dodged a potential setback recently when officials from the U.S. Department of Justice decided against joining a lawsuit alleging fraudulent medical practices. Burlington Northern Santa Fe Railway filed the original suit in 2019 against the center – known as the CARD Clinic – alleging Medicare fraud that included unnecessary screenings and misdiagnosing patients with various asbestos-related diseases. The railroad giant is facing more than a thousand asbestos-related injury claims stemming from its transportation of asbestos-laden products through its railyard ...
Source: Asbestos and Mesothelioma News - March 5, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Preparing $3.9 Billion for Talc Settlements
Pharmaceutical giant Johnson & Johnson has set aside $3.9 billion for talc-related litigation, according to a regulatory filing this week with the Securities and Exchange Commission in Washington D.C. The company said it’s now facing more than 25,000 lawsuits related to various talc products that have allegedly caused cancers, primarily from asbestos fiber contamination. The $3.9 billion is almost double the amount that Johnson & Johnson reported being set aside for litigation expenses in its 2020 fiscal year-end results. A Missouri Court of Appeals earlier last year upheld a lower-court ruling, but reduced the...
Source: Asbestos and Mesothelioma News - February 24, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system. The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test. “Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said. The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news